Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, the limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Granda-Díaz, Rocío, Martínez-Pérez, Alejandra, Aguilar-García, Candelaria, Rodrigo, Juan P., García-Pedrero, Juana M., Gonzalez, Segundo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466776/
https://www.ncbi.nlm.nih.gov/pubmed/37649037
http://dx.doi.org/10.1186/s12943-023-01845-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466776/
https://www.ncbi.nlm.nih.gov/pubmed/37649037
http://dx.doi.org/10.1186/s12943-023-01845-4

Ejemplares similares